The Supreme Court hears only a tiny fraction of the appeals it's invited to consider, and so it's more likely that if Novartis wants to move forward with Erelzi, then the biotech stock will have to work out some kind of deal with Amgen to do so.Even as competition continues to emerge in the streaming video space, shareholders have high hopes that Netflix has the first-mover edge to stay ahead of the pack well into the future.